Are We Prepared To Manage Anticoagulated ICH Patients or Should We Direct Them Elsewhere?

June 28, 2022
How and where to treat ICH patients- politics, reversal agents, and science all in one podcast!
1 Comments

AI in Imaging - We All Know It’s Coming. Are We Ready for the Machines in Stroke?

June 21, 2022
AI is coming but are we ready for it in stroke imaging?
0 Comments

Telemedicine and Stroke: What Have We Done?

June 14, 2022
Is telemedicine the savior for stroke care or the start part of the downfall of acute medicine?
0 Comments

Stroke Center Designations Are Big Business. Are They More Than That for Patient Care?

June 7, 2022
Stroke center designations are the currency of the realm; but does it matter to patients?
0 Comments

Telemedicine and Acute Stroke Research: What Is the State of the Union?

May 24, 2022

Telemedicine is the future of stroke - is it the future of stroke research?

0 Comments
RSS
245678910Last
Categories
More Entries

Aug 3

What Is the Clinical Impact of the Genetic Polymorphism Observed with the Effectiveness of some P2Y12 Inhibitors?

Haemin Go posted on 8/3/2021

Moderator:W. Brian Gibler, MD FACEP, FACC, FAHA
Other Participants: Deepak L. Bhatt, MD, MPH and Natalie Kreitzer, MD, MS

Role of genetic polymorphism in TIA and stroke is and has been controversial, since the initial introduction of clopidogrel. Hear Drs. Bhatt and Kreitzer discuss the basics and background associated with the metabolism of the various agents, where we have come, the management of ACSand also for acute ischemic stroke, the role of dual antiplatelet therapy (DAPT), pivotal trials such as THALES, PIVOT, and THEMIS, and the importance of closely monitoring for a recurrent stroke, which happens with high frequency within the 1st month post a stroke.

0 Comments
Please login or register to post comments.